# Intra-Osseous Co-Transplant of UCB and hMSC

> **NCT02181478** · EARLY_PHASE1 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 6 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Myelogenous Leukemia
- Myelodysplastic Syndromes
- Myelofibrosis
- Relapsed Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Relapsed Chronic Lymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Lymphoid Malignancies
- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate
- **RADIATION:** total-body irradiation
- **DRUG:** cyclosporine
- **DRUG:** mycophenolate mofetil
- **PROCEDURE:** umbilical cord blood transplantation
- **PROCEDURE:** mesenchymal stem cell transplantation

## Key facts

- **NCT ID:** NCT02181478
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-22
- **Primary completion:** 2019-12-19
- **Final completion:** 2020-02-07
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2020-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02181478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02181478, "Intra-Osseous Co-Transplant of UCB and hMSC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02181478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*